Medscape

In Global Trial, PCSK9 Inhibitor Provides Major Protection Against First CV Event

NEW ORLEANS — The first global randomized trial of the PCSK9 inhibitor evolocumab for the prevention of a primary major adverse cardiovascular event (MACE) found a relative reduction in risk similar ...
The American Journal of Managed Care

Oral PCSK9 Inhibitor Enlicitide Lowers LDL by 57% at 24 Weeks

CORALreef Lipids randomized 2,909 adults (2:1) to enlicitide 20 mg daily or placebo across 168 sites, using stratification by renal function, baseline statin use, and region. LDL-C at week 24 ...
Business Wire

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids ...
Business Wire

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial ...
The New England Journal of Medicine

A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data ...
Healio

Shifting PCSK9 inhibition ‘upstream’ for high-risk primary prevention

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibition demonstrated benefit in the broader primary prevention population for LDL lowering and plaque ...